0000950170-23-015767.txt : 20230428 0000950170-23-015767.hdr.sgml : 20230428 20230428160550 ACCESSION NUMBER: 0000950170-23-015767 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230410 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 23865904 BUSINESS ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 416-1192 MAIL ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 8-K/A 1 ubx-20230410.htm 8-K/A 8-K/A
0001463361true00014633612023-04-102023-04-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 10, 2023

 

 

UNITY BIOTECHNOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38470

26-4726035

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

285 East Grand Ave.

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 416-1192

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

UBX

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. As reported on April 11, 2023, the Company and Jamie Dananberg agreed that Dr. Dananberg would be leaving his employment with the Company on April 30, 2023. In connection with his departure as an employee on April 30, 2023, the Company and Dr. Dananberg entered into a Separation Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will receive, in addition to any accrued obligations, (i) a severance payment equal to nine months of his base salary in a lump sum payment and (ii) continued health care coverage for himself and his covered dependents under the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, until the earlier of the nine month anniversary of his separation date or the date he becomes eligible for healthcare coverage from another employer. Dr. Dananberg has agreed to provide a full release of claims in favor of the Company. In addition, the Company and Dr. Dananberg entered into a Consulting Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will continue to provide advice and assistance with the Company’s clinical development programs and related matters in exchange for continued vesting of his equity awards and compensation at the rate of $500 per hour for services rendered above and beyond a monthly eight-hour threshold.

 

The foregoing is only a summary of the material terms of the Separation Agreement and the Consulting Agreement and is qualified in its entirety by reference to the respective agreements, which the Company expects to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

UNITY BIOTECHNOLOGY, INC.

 

 

 

 

Date:

April 28, 2023

By:

/s/ Anirvan Ghosh

 

 

 

Anirvan Ghosh, Ph.D.
Chief Executive Officer

 

 

 EX-101.LAB 2 ubx-20230410_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Soliciting Material Entity Ex Transition Period Amendment Flag Entity Incorporation, State or Country Code City Area Code Document Period End Date Entity Address, Postal Zip Code Securities Act File Number Entity Address, Address Line One Entity Tax Identification Number Entity Emerging Growth Company Amendment Description Entity Registrant Name Pre-commencement Tender Offer Title of 12(b) Security Entity Address, State or Province Document Type Written Communications Security Exchange Name Entity Central Index Key Local Phone Number Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol EX-101.PRE 3 ubx-20230410_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 ubx-20230410.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Apr. 10, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. As reported on April 11, 2023, the Company and Jamie Dananberg agreed that Dr. Dananberg would be leaving his employment with the Company on April 30, 2023. In connection with his departure as an employee on April 30, 2023, the Company and Dr. Dananberg entered into a Separation Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will receive, in addition to any accrued obligations, (i) a severance payment equal to nine months of his base salary in a lump sum payment and (ii) continued health care coverage for himself and his covered dependents under the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, until the earlier of the nine month anniversary of his separation date or the date he becomes eligible for healthcare coverage from another employer. Dr. Dananberg has agreed to provide a full release of claims in favor of the Company. In addition, the Company and Dr. Dananberg entered into a Consulting Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will continue to provide advice and assistance with the Company’s clinical development programs and related matters in exchange for continued vesting of his equity awards and compensation at the rate of $500 per hour for services rendered above and beyond a monthly eight-hour threshold.  The foregoing is only a summary of the material terms of the Separation Agreement and the Consulting Agreement and is qualified in its entirety by reference to the respective agreements, which the Company expects to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
Document Period End Date Apr. 10, 2023
Entity Registrant Name UNITY BIOTECHNOLOGY, INC.
Entity Central Index Key 0001463361
Entity Emerging Growth Company true
Securities Act File Number 001-38470
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4726035
Entity Address, Address Line One 285 East Grand Ave.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 416-1192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol UBX
Security Exchange Name NASDAQ
XML 6 ubx-20230410_htm.xml IDEA: XBRL DOCUMENT 0001463361 2023-04-10 2023-04-10 0001463361 true 8-K/A 2023-04-10 UNITY BIOTECHNOLOGY, INC. DE 001-38470 26-4726035 285 East Grand Ave. South San Francisco CA 94080 (650) 416-1192 false false false false Common Stock, par value $0.0001 per share UBX NASDAQ true false This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. As reported on April 11, 2023, the Company and Jamie Dananberg agreed that Dr. Dananberg would be leaving his employment with the Company on April 30, 2023. In connection with his departure as an employee on April 30, 2023, the Company and Dr. Dananberg entered into a Separation Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will receive, in addition to any accrued obligations, (i) a severance payment equal to nine months of his base salary in a lump sum payment and (ii) continued health care coverage for himself and his covered dependents under the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, until the earlier of the nine month anniversary of his separation date or the date he becomes eligible for healthcare coverage from another employer. Dr. Dananberg has agreed to provide a full release of claims in favor of the Company. In addition, the Company and Dr. Dananberg entered into a Consulting Agreement, dated April 27, 2023, pursuant to which Dr. Dananberg will continue to provide advice and assistance with the Company’s clinical development programs and related matters in exchange for continued vesting of his equity awards and compensation at the rate of $500 per hour for services rendered above and beyond a monthly eight-hour threshold.  The foregoing is only a summary of the material terms of the Separation Agreement and the Consulting Agreement and is qualified in its entirety by reference to the respective agreements, which the Company expects to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports ubx-20230410.htm ubx-20230410.xsd ubx-20230410_lab.xml ubx-20230410_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ubx-20230410.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ubx-20230410.htm" ] }, "labelLink": { "local": [ "ubx-20230410_lab.xml" ] }, "presentationLink": { "local": [ "ubx-20230410_pre.xml" ] }, "schema": { "local": [ "ubx-20230410.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ubx", "nsuri": "http://unitybiotechnology.com/20230410", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ubx-20230410.htm", "contextRef": "C_8b924644-03b7-4faa-843c-bbec798ef788", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ubx-20230410.htm", "contextRef": "C_8b924644-03b7-4faa-843c-bbec798ef788", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20230410/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-015767-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-015767-xbrl.zip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end